v3.25.2
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2023   70,767,000        
Beginning balance at Dec. 31, 2023 $ 437,391 $ 70 $ 1,323,576 $ 2,194 $ (888,556) $ 107
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Share-based compensation expense 25,544   25,544      
Other comprehensive loss (2,054)     (2,054)    
Issuance and withholding of common stock in connection with restricted stock unit vesting, net (in shares)   322,000        
Issuance and withholding of common stock in connection with restricted stock unit vesting, net (240) $ 1 (241)      
Deconsolidation of Kalyra (79)         (79)
Shares issued under employee stock purchase plan (in shares)   18,000        
Shares issued under employee stock purchase plan 248   248      
Net loss attributable to non-controlling interest (28)         (28)
Net loss attributable to Zentalis (78,209)       (78,209)  
Ending balance (in shares) at Jun. 30, 2024   71,107,000        
Ending balance at Jun. 30, 2024 382,581 $ 71 1,349,135 140 (966,765) 0
Beginning balance (in shares) at Mar. 31, 2024   71,013,000        
Beginning balance at Mar. 31, 2024 458,771 $ 70 1,336,416 773 (878,488)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Share-based compensation expense 12,711   12,711      
Other comprehensive loss (633)     (633)    
Issuance and withholding of common stock in connection with restricted stock unit vesting, net (in shares)   94,000        
Issuance and withholding of common stock in connection with restricted stock unit vesting, net 1 $ 1 0      
Issuance of common stock upon exercise of options, net 8   8      
Net loss attributable to non-controlling interest 0          
Net loss attributable to Zentalis (88,277)       (88,277)  
Ending balance (in shares) at Jun. 30, 2024   71,107,000        
Ending balance at Jun. 30, 2024 $ 382,581 $ 71 1,349,135 140 (966,765) $ 0
Beginning balance (in shares) at Dec. 31, 2024 71,282,400 71,282,000        
Beginning balance at Dec. 31, 2024 $ 337,186 $ 71 1,390,952 558 (1,054,395)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Share-based compensation expense 12,772   12,772      
Other comprehensive loss (499)     (499)    
Issuance and withholding of common stock in connection with restricted stock unit vesting, net (in shares)   714,000        
Issuance and withholding of common stock in connection with restricted stock unit vesting, net 0 $ 1 (1)      
Shares issued under employee stock purchase plan (in shares)   139,000        
Shares issued under employee stock purchase plan 189   189      
Net loss attributable to non-controlling interest 0          
Net loss attributable to Zentalis $ (75,153)       (75,153)  
Ending balance (in shares) at Jun. 30, 2025 72,135,453 72,135,000        
Ending balance at Jun. 30, 2025 $ 274,495 $ 72 1,403,912 59 (1,129,548)  
Beginning balance (in shares) at Mar. 31, 2025   71,951,000        
Beginning balance at Mar. 31, 2025 295,382 $ 72 1,397,626 358 (1,102,674)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Share-based compensation expense 6,286   6,286      
Other comprehensive loss (299)     (299)    
Issuance and withholding of common stock in connection with restricted stock unit vesting, net (in shares)   184,000        
Net loss attributable to non-controlling interest 0          
Net loss attributable to Zentalis $ (26,874)       (26,874)  
Ending balance (in shares) at Jun. 30, 2025 72,135,453 72,135,000        
Ending balance at Jun. 30, 2025 $ 274,495 $ 72 $ 1,403,912 $ 59 $ (1,129,548)